Evidence map›Paper›PMID 42044466›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Lara Stepan, Sahar Ansari, Jeremy S Abramson, Abood Okal, Justine Dell'Aringa, Ethan G Thompson, Alessandro Crotta, Victor A Chow, Manali Kamdar, Scott R Solomon and 14 more

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03575351 (A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03575351 phase3completednot on this map

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

TypeinterventionalSponsorCelgeneRan2018 to 2023Enrolled184ConditionsLymphoma, Non-HodgkinArmsStandard of Care, JCAR017
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lara StepanBristol Myers Squibb, Seattle, WA.
Sahar AnsariBristol Myers Squibb, Seattle, WA.
Jeremy S AbramsonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8467-9257
Abood OkalBristol Myers Squibb, Cambridge, MA.
Justine Dell'AringaBristol Myers Squibb, Seattle, WA.
Ethan G ThompsonBristol Myers Squibb, Seattle, WA.
Alessandro CrottaBristol Myers Squibb, Boudry, Switzerland.
Victor A ChowBristol Myers Squibb, Seattle, WA.
Manali KamdarUniversity of Colorado Cancer Center, Aurora, CO.ORCID 0000-0002-1930-152X
Scott R SolomonNorthside Hospital Cancer Institute, Atlanta, GA.ORCID 0000-0003-2061-8126
Patrick B JohnstonMayo Clinic, Rochester, MN.ORCID 0000-0002-3212-3510
Bertram GlassHelios Klinikum Berlin-Buch, Berlin, Germany.ORCID 0009-0000-0816-688X
Pim MutsaersErasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0002-3924-8578
Jon ArnasonBeth Israel Deaconess Medical Center, Boston, MA.
Stephan MielkeKarolinska Institutet and University Hospital; Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden.ORCID 0000-0002-8325-9215
Mazyar ShadmanFred Hutch Cancer Center, University of Washington, Seattle, WA.ORCID 0000-0002-3365-6562
Francisco Hernandez-IlizaliturriRoswell Park Comprehensive Cancer Center, Buffalo, NY.
Koji IzutsuNational Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-9129-8057
Veronika BachanovaUniversity of Minnesota, Minneapolis, MN.ORCID 0000-0002-9325-432X
Sami IbrahimiUniversity of Oklahoma Stephenson Cancer Center, Oklahoma City, OK.ORCID 0000-0002-7538-346X
Jacob J ChabonForesight Diagnostics, Aurora, CO.
David M KurtzStanford University, Palo Alto, CA.ORCID 0000-0002-6382-4651
Ash A AlizadehStanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, CA.ORCID 0000-0002-5153-5625
Leanne PeiserBristol Myers Squibb, Seattle, WA.ORCID 0009-0007-2996-6369

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD]

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCirculating Tumor DNAHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAdultFemaleHumansMaleMiddle AgedNeoplasm, ResidualProgression-Free SurvivalTransplantation, AutologousCirculating Tumor DNA

Identifiers

PMID42044466
PMCPMC13313472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.